Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Breast Cancer (Tokyo, Japan)|May 23, 2002
An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancerReiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 23, 2014
[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)]Yutaka Yamamoto, Reiki Nishimura, Tomio Tanigawa, et al.
Anti-Cancer Drugs|January 16, 2010
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II studyMaki Tanaka, Yasushi Takamatsu, Keisei Anan, et al.
Breast Cancer (Tokyo, Japan)|January 15, 2003
Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective studyJunichi Kurebayashi, Yutaka Yamamoto, Katsuhiro Tanaka, et al.
Journal of Clinical Pathology|October 1, 2015
The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 indexNobuyuki Arima, Reiki Nishimura, Tomofumi Osako, et al.
International Journal of Clinical Oncology|April 10, 2015
Efficacy of intraoperative entire-circumferential frozen section analysis of lumpectomy margins during breast-conserving surgery for breast cancerTomofumi Osako, Reiki Nishimura, Yasuyuki Nishiyama, et al.
Plos One|July 16, 2015
Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective StudyRumiko Tashima, Reiki Nishimura, Tomofumi Osako, et al.
Oncology|November 28, 2015
A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast CancerNobuyuki Arima, Reiki Nishimura, Tomofumi Osako, et al.
Chemotherapy|May 12, 2005
Weekly paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II studyReiki Nishimura, Takahiro Ogawa, Masato Kato, et al.
Cancer Medicine|May 19, 2020
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 studyMasato Takahashi, Norikazu Masuda, Reiki Nishimura, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Breast Cancer (Tokyo, Japan)|May 23, 2002
An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancerReiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 23, 2014
[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)]Yutaka Yamamoto, Reiki Nishimura, Tomio Tanigawa, et al.
Anti-Cancer Drugs|January 16, 2010
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II studyMaki Tanaka, Yasushi Takamatsu, Keisei Anan, et al.
Breast Cancer (Tokyo, Japan)|January 15, 2003
Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective studyJunichi Kurebayashi, Yutaka Yamamoto, Katsuhiro Tanaka, et al.
Journal of Clinical Pathology|October 1, 2015
The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 indexNobuyuki Arima, Reiki Nishimura, Tomofumi Osako, et al.
International Journal of Clinical Oncology|April 10, 2015
Efficacy of intraoperative entire-circumferential frozen section analysis of lumpectomy margins during breast-conserving surgery for breast cancerTomofumi Osako, Reiki Nishimura, Yasuyuki Nishiyama, et al.
Plos One|July 16, 2015
Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective StudyRumiko Tashima, Reiki Nishimura, Tomofumi Osako, et al.
Oncology|November 28, 2015
A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast CancerNobuyuki Arima, Reiki Nishimura, Tomofumi Osako, et al.
Chemotherapy|May 12, 2005
Weekly paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II studyReiki Nishimura, Takahiro Ogawa, Masato Kato, et al.
Cancer Medicine|May 19, 2020
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 studyMasato Takahashi, Norikazu Masuda, Reiki Nishimura, et al.
Pageof 8